Director
Moderna Therapeutics
I am a director in the Bioanalytical and Molecular Assay department at Moderna, leading a group of scientists to develop, validate and implement robust LCMS assays critical to advancing Moderna's mRNA-based therapies. I received Ph.D. in analytical chemistry and have more than 20 years of industry experience in LCMS-based bioanalysis. I worked for several CROs between 2004 to 2016, including LabCorp and CRL, specializing in regulated small molecule LCMS-based method development and validation. In 2017 I joined Shire/Takeda's clinical biomarker department. Over there, I contributed to multiple regulatory submissions, including the NDA filing of Maribavir (LIVTENCITY), which the FDA approved in 2021. Before joining Moderna, I was a director of the bioanalytical and biomarker department at Wave life Science, a company delivering antisense oligonucleotide therapies to treat rare diseases